Critical Path for Parkinson’s (CPP) members met on June 18th in Berlin for the First Annual Consortium Member Meeting

Critical Path for Parkinson’s (CPP) members met on June 18th in Berlin for the First Annual Consortium Member Meeting. A group of 34 world leading experts from industry, academia and patient advocacy organizations convened for a day to discuss the progress to date and the future scope of the multinational consortium. Themes included recognition of early intervention, critical role of data standards, data sharing, modeling and new technologies in the advancement of PD therapies. The venue was held in advance of the 20th International Congress for the Movement Disorders Society (MDS) meeting where CPP was featured in three presentations. The global nature of the conference and location provided an ideal venue for multinational stakeholders to engage in active and dynamic discussion, centered around the importance of collaboration in advancing new treatments for PD.

	Critical Path for Parkinson’s I: Data Sharing and Regulatory Science in Catalyzing Innovation for Parkinson’s Disease
	Critical Path for Parkinson’s II: Global Regulatory Agencies Support the Use of Dopamine Transporter Neuroimaging as an Enrichment Biomarker to Enable Clinical Trials in Early Parkinson’s Disease
	Critical Path for Parkinson’s III: Lessons-experienced in the creation of a global public-private consortium with the goal of advancing treatments that hold most potential for delayed disease progression in Parkinson’s Disease – Critical Path for Parkinson’s (CPP)